Syros Pharmaceuticals Inc
(87184Q107)
ファンドの報告 Syros Pharmaceuticals Inc 13F提出書類による
| 商号 | 保有株式/元本 | 市場価格 | オプション | 報告期間 | 有効日 |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 3,791,756 | $35,112k | Jun 30, 2019 | Jul 30, 2019 | |
| Redmile Group LLC | 3,620,376 | $33,525k | Jun 30, 2019 | Aug 14, 2019 | |
| Nikko Asset Management Americas Inc | 2,987,763 | $27,667k | Jun 30, 2019 | Jul 29, 2019 | |
| Deerfield Management Company LP Series C | 1,268,946 | $11,750k | Jun 30, 2019 | Aug 14, 2019 | |
| Baker BROS Advisors LP | 974,835 | $9,027k | Jun 30, 2019 | Aug 14, 2019 | |
| 683 Capital Management LLC | 429,775 | $3,980k | Jun 30, 2019 | Aug 14, 2019 | |
| Ecor1 Capital LLC | 248,480 | $2,301k | Jun 30, 2019 | Aug 14, 2019 | |
| Prelude Capital Management LLC | 1,189 | $11k | Jun 30, 2019 | Aug 14, 2019 |